Published briefing
Investec Discloses 5,000-Share Purchase, Sep 14
Investec Bank Plc disclosed a purchase of 5,000 ordinary shares on 14th September 2026, filed under a disclosure dated 15th September 2026.
PipDig Newsroom ·
Read briefingMarket News
The following Forex news reports are the latest developments of the Forex market. The news reports are updated frequently and include all the events that affect the foreign exchange trading industry.
More briefings
Published briefing
Fluke Expands iSee Series With TC03A and ii01 Cameras
Fluke Corporation expanded its iSee Mobile Imaging Series with the TC03A thermal camera and ii01 acoustic camera.
Read briefing
Published briefing
Ascendis Pharma Launches Share Repurchase Program
Ascendis Pharma A/S announced a share repurchase program on September 14, 2026, that carries no mandatory purchase requirement.
Read briefingPublished briefing
Blue Jay Gold Reports Skukum Creek Assay Results
Blue Jay Gold Corp reported 200-sample assays from Skukum Creek and Mt. Skukum, confirming a down-plunge extension at SC26-003.
Read briefing
Published briefing
Home Bancshares Sets Oct. 14, 2026 Earnings Call
Home Bancshares, Inc. (HOMB) will release its third-quarter results on October 14, 2026.
Read briefing
Published briefing
Zoom Launches 'Got It Done' Ad With Kate McKinnon
Zoom's Got It Done campaign features Kate McKinnon and aired during NFL Monday Night Football, Week 1, according to the company.
Read briefing
Published briefing
Ferrari Reports Progress in Third Buyback Tranche
Ferrari has repurchased 1,779,532 shares since its buyback program began on Jan 5, 2026, based on a single disclosed report.
Read briefing
Published briefing
Ernexa CEO to Present at H.C. Wainwright Conference
Ernexa Therapeutics CEO Sanjeev Luther will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 12:00 p.m. ET, covering the company's oncology strategy and ERNA-101 progress.
Read briefing
Published briefing
Daré's Sildenafil Cream shows lower plasma levels in Phase 1
Daré Bioscience (NASDAQ: DARE) reported Phase 1 data: its 71 mg Sildenafil Cream showed peak plasma levels 187-fold lower than oral sildenafil.
Read briefing